#NexeraPharmaCoLtd

Achieved primary endpoints in the Phase III trial of Daridorexant in South Korea; manufacturing and marketing approval application planned for Q1 2026, with approval expected in Q1 2027.

Nexera Pharma has received a $3.6 million (approximately ¥565 million) milestone from Centessa and plans to record it as revenue in the fourth quarter of the fiscal year ending December 2025.